Myriad Genetics Inc (MYGN)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Based on the data provided for Myriad Genetics Inc, the Days Sales Outstanding (DSO) ratio is not available or provided for analysis for any of the reporting periods from March 31, 2020, to December 31, 2024.
DSO is a financial metric used to evaluate how efficiently a company is managing its accounts receivable. A low DSO indicates that the company is collecting payments quickly, while a high DSO suggests a longer cycle for collecting payments from customers.
Unfortunately, without the specific DSO values for Myriad Genetics Inc across the reported periods, it is challenging to assess the company's effectiveness in collecting receivables and managing its cash flow. It is recommended to monitor and analyze this ratio in future financial reports to gain insights into the company's credit and collection policies, as well as its overall financial health.
Peer comparison
Dec 31, 2024